Armis Named a Leader for Second Consecutive Year in 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms
4.3.2026 16:12:00 CET | Business Wire | Press Release
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year.
“In an era of agentic AI, the security of our cyber-physical systems has become a strategic imperative for enterprises and governments globally; it is a pivotal pillar of global stability,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe this back-to-back recognition from Gartner reflects our continued commitment to helping organizations secure the complex, critical world of CPS and reinforces the strength of our unified, proactive platform approach. Our innovation pipeline, which is aligned with our customers' needs, will continue to prioritize protecting critical environments to keep society safe and secure.”
Armis was named a Leader in this report among the 13 vendors that were evaluated. Armis Centrix™, the Armis Cyber Exposure Management Platform, was evaluated within the report for its Completeness of Vision and Ability to Execute.
We believe Armis distinguishes itself through a broad, proactive platform designed to understand the entire environment rather than offering narrow, siloed monitoring. Armis Centrix™ was specifically engineered to manage the complex risks of CPS, providing a unified understanding of exposures across every domain. This approach replaces fragmented point solutions with a single, contextualized view that aligns cybersecurity directly with an organization's operational realities.
As of March 3, 2026, Armis had 119 reviews on Gartner Peer Insights™ in the CPS Protection Platform category with an overall rating of 4.7 out of 5. Armis customers praise the company’s CPS Protection Platform solution through verified ratings and reviews on Gartner® Peer Insights:
“Excellent product suite that reveals insights never seen or thought to even look for that really brings a holistic view into the enterprise surface of any sized organization.” - IT Associate (Industry: Construction)
Security solutions have historically been designed to address specific technology silos. However, cyber risk no longer respects these boundaries. Exposures frequently emerge from the interactions between systems, where vulnerabilities, misconfigurations, identities, and dependencies intersect across multiple asset classes.
“Our customers in OT-driven industries acknowledge that CPS security now extends beyond conventional OT boundaries,” said Nadir Izrael, CTO and Co-Founder of Armis. “Security strategies built around isolated areas risk missing the broader exposure landscape that organizations must now manage. As a result, to meet CPS security demands, organizations require a platform designed to deliver holistic protection, which Armis offers.”
As CPS security requirements continue to mature, organizations are demanding greater flexibility in how security platforms are deployed. Operational constraints, regulatory obligations, and architectural preferences vary widely across industries. To address these realities, Armis offers on-premises, cloud, and hybrid deployment options. This flexibility enables organizations to align Armis Centrix™ with their infrastructure strategies while maintaining a consistent, unified security model.
Find more information about Armis Centrix™, the Cyber Exposure Management Platform, here.
For additional analyst reports recognizing Armis, please visit our Analyst Relations webpage.
Gartner Disclaimer
Gartner, 2026 Gartner® Magic Quadrant™ for CPS Protection Platforms, Katell Thielemann, Wam Voster, Ruggero Contu, Sumit Rajput, March 3, 2026. Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world, Armis ensures that organizations continuously see, protect and manage all critical assets — from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies, as well as national governments and state and local entities, to help keep critical infrastructure, economies and society safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304220653/en/
Contacts
Media Contacts:
Rebecca Cradick
Vice President, Global Communications
Armis
pr@armis.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom